Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11311089 | 0.84 | CA2 (0.45) | CA2CA12CA9CA1 | |
| SCHEMBL3660541 | 0.79 | CA2 (0.38) | CA2CA12CA9CA1 | |
| SCHEMBL1956114 | 0.78 | CA2 (0.61) | CA2CA12CA9CA1 | |
| SCHEMBL3975249 | 0.77 | PRSS1 (0.37) | CA2CA1 | |
| SCHEMBL9158772 | 0.77 | CA12 (0.38) | CA2CA12CA9 | |
| SCHEMBL9743508 | 0.77 | ALDH1A1 (0.52) | CA2CA12CA9CA1 | |
| SCHEMBL2183092 | 0.77 | CA2 (0.59) | CA2CA12CA9CA1 | |
| SCHEMBL5387257 | 0.76 | CA2 (0.36) | CA2CA12CA9CA1 | |
| SCHEMBL1485836 | 0.75 | TSHR (0.45) | CA2CA12CA9CA1 | |
| SCHEMBL5175495 | 0.75 | MAPT (0.52) | CA2CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2008073451-A2 | BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | CA2 3931/4885CA12 2502/4885CA9 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.